Incyte is focused on advancing biopharmaceutical innovation.
Founded in 2002 with a small number of scientists, chemists and biologists in Wilmington, Delaware, Incyte has grown into a global organization with a robust portfolio of treatments across Hematology, Oncology and Inflammation and Autoimmunity. Today, the company has more than 2,800 employees and operations in 13 countries across North America, Europe and Asia.
Our goal is to develop breakthrough medicines that improve patients' lives. With patients at the center of everything we do, our discovery approach focuses on building a portfolio of compounds that are scientifically differentiated and poised to make a meaningful impact.
At Incyte, we aim to foster a workplace grounded in respect, curiosity and accountability. We are proud to have been named among the Top Employers by Science magazine for 8 consecutive years, as well as being named one of the Global Top 100 Most Loved Workplaces and America’s Top 100 Most Loved Workplaces by Newsweek and the Best Practice Institute.
To learn more, visit Incyte.com and Investor.Incyte.com. Follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube.
See our Community Guidelines: http://bit.ly/2sV0H5W
bluebird bio has rebranded as Genetix Biotherapeutics, returning to our foundational roots and renewing our commitment to delivering transformative genetic therapies for patients living with sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy.
Follow our new page at the link below!
Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. We currently market two autologous cell therapy products and one specialty biologic product in the United States.
Personal integrity, teamwork, collaboration, and innovative technology are the foundations of our work. We seek to practice transparency in our clinical trials and research, and in our relationships with each other, our patients, and the investors who support us.
PRIVACY AND COMMUNITY GUIDELINES
When you engage with Vericel social media channels and our content providers on social media, you also agree to abide by the following Community Guidelines (found here: https://bit.ly/3pg3UKQ), which apply in addition to the Terms and Conditions or other legal notices specific to each social media channel.
Please note that third-party social media channels also have access to information you share via social media. For more details, read LinkedIn's Privacy Policy here: https://bit.ly/3GF2r5Y. For additional information about privacy at Vericel, please see our Privacy Policy (bit.ly/43ErZcx) and Terms and Conditions of Use (bit.ly/4568Cdx).
If you engage with us, you consent and give Vericel permission to communicate with you and to use any information, text and media associated with the interaction or post.
Get contact details of over 700M profiles across 60M
companies – all with industry-leading accuracy. Sales and Recruiter users, try out our
Email Finder Extension.
Find business and personal emails and mobile phone numbers
with exclusive coverage across niche job titles, industries, and more
for unparalleled targeting. Also
available via our
Contact Data API.